MX9603560A - Composiciones de prostaglandinas estables en almacenamiento. - Google Patents

Composiciones de prostaglandinas estables en almacenamiento.

Info

Publication number
MX9603560A
MX9603560A MX9603560A MX9603560A MX9603560A MX 9603560 A MX9603560 A MX 9603560A MX 9603560 A MX9603560 A MX 9603560A MX 9603560 A MX9603560 A MX 9603560A MX 9603560 A MX9603560 A MX 9603560A
Authority
MX
Mexico
Prior art keywords
storage
prostaglandin compositions
stable prostaglandin
compositions
stable
Prior art date
Application number
MX9603560A
Other languages
English (en)
Other versions
MXPA96003560A (es
Inventor
Schneider L Wayne
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23427079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9603560(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of MXPA96003560A publication Critical patent/MXPA96003560A/es
Publication of MX9603560A publication Critical patent/MX9603560A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

El uso de aceites de ricino polietoxilado en las composiciones de prostaglandina aumenta considerablemente la estabilidad química de la prostaglandina.
MX9603560A 1994-12-22 1996-08-21 Composiciones de prostaglandinas estables en almacenamiento. MX9603560A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08362677 1994-12-22
US08/362,677 US5631287A (en) 1994-12-22 1994-12-22 Storage-stable prostaglandin compositions

Publications (2)

Publication Number Publication Date
MXPA96003560A MXPA96003560A (es) 1998-01-01
MX9603560A true MX9603560A (es) 1998-01-31

Family

ID=23427079

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603560A MX9603560A (es) 1994-12-22 1996-08-21 Composiciones de prostaglandinas estables en almacenamiento.

Country Status (12)

Country Link
US (2) US5631287A (es)
EP (1) EP0812198B1 (es)
JP (3) JP3631255B2 (es)
AT (1) ATE208621T1 (es)
AU (1) AU700574B2 (es)
CA (1) CA2181172C (es)
DE (1) DE69523951T2 (es)
DK (1) DK0812198T3 (es)
ES (1) ES2162951T3 (es)
MX (1) MX9603560A (es)
PT (1) PT812198E (es)
WO (1) WO1997029752A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) † 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
EP1007028A4 (en) * 1997-05-09 2002-06-05 TREATING GLAUCOMA WITH 8 ISO PROSTAGLANDINE
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
CA2295512C (en) * 1998-07-14 2009-05-26 Alcon Laboratories, Inc. Prostaglandin product
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7166730B2 (en) * 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
EP1321144B1 (en) * 2000-09-13 2010-12-08 Santen Pharmaceutical Co., Ltd. Eye drops
JP4261912B2 (ja) 2001-04-19 2009-05-13 テイカ製薬株式会社 薬剤および薬剤キット
WO2003079997A2 (en) * 2002-03-21 2003-10-02 Cayman Chemical Company Prostaglandin f2 alpha analogs in combinaiotn with antimicrobials for treating glaucoma
US20040079671A1 (en) * 2002-08-29 2004-04-29 Paramita Bandyopadhyay Medicinal product packaging
EP1547599B1 (en) * 2002-09-09 2017-11-01 Santen Pharmaceutical Co., Ltd. Transparent eye drops containing latanoprost
DE602004023106D1 (de) 2003-11-07 2009-10-22 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
GB0329620D0 (en) * 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
DK1759702T3 (da) 2004-05-26 2009-04-20 Bayardo Arturo Jimenez Fremgangsmåde til fremstilling af en latanoprost-öjenoplösning og en således fremstillet oplösning
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
WO2008052031A2 (en) * 2006-10-24 2008-05-02 Alcon Research, Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
JPWO2008096804A1 (ja) 2007-02-07 2010-05-27 テイカ製薬株式会社 ラタノプロスト含有点眼剤
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
EP2197449A4 (en) * 2007-10-16 2013-10-09 Sun Pharma Advanced Res Co Ltd NOVEL OPHTHALMIC COMPOSITIONS
EP2077105A1 (en) 2008-01-02 2009-07-08 Novagali Pharma SA Ophthalmic Micellar Compositions with Enhanced Stability
EP2077104A1 (en) 2008-01-02 2009-07-08 Novagali Pharma SA Micellar compositions with ophtalmic applications
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
BRPI0909738A2 (pt) 2008-03-17 2015-10-06 Alcon Res Ltd composições farmacêuticas aquosas contendo complexos de boratopoliol
JP2009256281A (ja) * 2008-04-21 2009-11-05 Teika Seiyaku Kk イソプロピルウノプロストン含有点眼剤組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
RU2012124216A (ru) * 2009-11-11 2013-12-20 Микро Лабс Лимитед Фармацевтическая комбинация соединения простагландина и nsaid для лечения глаукомы и глазной гипертензии
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
EP3378480A1 (en) 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Methods and compositions for treating obesity
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
ITRM20120036A1 (it) * 2012-02-02 2013-08-03 Robert Davis Steigerwalt Jr Applicazione transdermica di prostaglandina e1 per il trattamento dell¿ischemia oculare.
CN104936595A (zh) 2012-11-21 2015-09-23 托普凯恩制药公司 局部增加体脂肪的方法和组合物
NO2753788T3 (es) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
SG11201605532YA (en) * 2014-01-10 2016-08-30 Santen Pharmaceutical Co Ltd Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
MX2016009049A (es) * 2014-01-10 2016-09-09 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
CA2999988C (en) 2015-09-27 2024-06-11 Follica, Inc. Needling device and drug applicator
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2526938C2 (de) * 1975-02-14 1982-04-22 F. Hoffmann-La Roche & Co. AG, 4002 Basel Vitaminpräparate
JPS6046094B2 (ja) * 1977-06-01 1985-10-14 科研製薬株式会社 安定化されたプロスタグランジンｅ類粉末製剤
JPS59216820A (ja) * 1983-05-20 1984-12-06 Taisho Pharmaceut Co Ltd プロスタグランジン脂肪乳剤
DE3347128A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 9-halogen-(delta)(pfeil hoch)2(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3510978A1 (de) * 1985-03-22 1986-09-25 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
JPH0669966B2 (ja) * 1989-07-05 1994-09-07 株式会社ミドリ十字 血管造影補助剤
JPH03101622A (ja) * 1989-09-11 1991-04-26 Green Cross Corp:The 肝炎予防治療剤
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
JP3256997B2 (ja) * 1990-08-30 2002-02-18 千寿製薬株式会社 安定な水性製剤
EP0664707B1 (en) * 1992-10-13 1997-06-04 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension

Also Published As

Publication number Publication date
PT812198E (pt) 2002-02-28
JP2005015498A (ja) 2005-01-20
CA2181172C (en) 2003-04-29
JPH11500122A (ja) 1999-01-06
ATE208621T1 (de) 2001-11-15
AU4649596A (en) 1997-09-02
WO1997029752A1 (en) 1997-08-21
AU700574B2 (en) 1999-01-07
JP2010043131A (ja) 2010-02-25
CA2181172A1 (en) 1996-06-23
DE69523951D1 (de) 2001-12-20
DK0812198T3 (da) 2002-03-18
US5849792A (en) 1998-12-15
US5631287A (en) 1997-05-20
DE69523951T2 (de) 2002-04-04
JP3631255B2 (ja) 2005-03-23
EP0812198B1 (en) 2001-11-14
ES2162951T3 (es) 2002-01-16
EP0812198A1 (en) 1997-12-17

Similar Documents

Publication Publication Date Title
MX9603560A (es) Composiciones de prostaglandinas estables en almacenamiento.
HUP9903174A2 (hu) Koenzim Q-10-et tartalmazó gyógyászati készítmény
AU1666188A (en) Deodorizing and antimicrobial composition for use in cosmetic or topical formulations
TW280773B (es)
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
AU652217B2 (en) Cosmetic composition
NO964966L (no) Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav
PT1308170E (pt) Composição seca de factor sanguíneo que compreende trealose
GR3007385T3 (es)
IL98156A0 (en) Pharmaceutical compositions containing magnesium-pyridoxal-5'-phosphate-glutaminate
AU4926690A (en) Oxidized diphenylheteroalkanes, the preparation and use thereof
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
CA2061995A1 (en) Use of oxime ether derivatives for bioregulation in plants
PH27567A (en) Topical compositions
YU46914B (sh) Metoksimetilna jedinjenja
TW218011B (es)
ATE195055T1 (de) Insektizide zusammensetzung die diatomeenerde und siliziumdioxid enthalten
MX9703288A (es) Oxazolil- y tiazolilimidazo-benzo- y tienodiacepinas y su uso como medicamentos.
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
DE69813165D1 (de) Hautdepigmentierungsmittel
AU3992897A (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders
AU587293B2 (en) 5-heterocyclic-2,4-dialkyl-3H-1,2,4-triazole-3-thiones and their use as antidepressants
ES8500928A1 (es) Procedimiento para la obtencion de oxaspirododecan-derivados de efecto perfumante
AU587645B2 (en) 5-naphthyl-2,4-dialkyl-3H-1,2,4-triazole-3-thiones and their use as antidepressants